Structural basis of cholecystokinin receptor binding and regulation

Pharmacology and Therapeutics

Volumn 119, Issue 1, 2008, Pages 83-95

  Miller, Laurence J ^a   Gao, Fan ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Cholecystokinin; Gastrin; GPCR; Molecular modeling; Photoaffinity labeling

Indexed keywords

BENZODIAZEPINE; CHIMERIC PROTEIN; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR 1; CHOLECYSTOKININ RECEPTOR 2; GASTRIN; PROTEIN KINASE C; RHODOPSIN;

AMINO ACID SEQUENCE; BINDING AFFINITY; BINDING SITE; CELL MEMBRANE; CELL SURFACE; DESENSITIZATION; FLUORESCENCE; HUMAN; LIGAND BINDING; MICROENVIRONMENT; MUTAGENESIS; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CHOLECYSTOKININ;

EID: 46149118170     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.05.001     Document Type: Review

References (100)

1. Anders J., Bluggel M., Meyer H.E., Kuhne R., Ter Laak A.M., Kojro E., et al. Direct identification of the agonist binding site in the human brain cholecystokininB receptor. Biochemistry 38 (1999) 6043-6055
2. Aquino C.J., Armour D.R., Berman J.M., Birkemo L.S., Carr R.A.E., Croom D.K., et al. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "Trigger". J Med Chem 39 (1996) 562-569
3. Arlander S.J., Dong M., Ding X.Q., Pinon D.I., and Miller L.J. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist. Mol Pharmacol 66 (2004) 545-552
4. Behar J., Rhim B.Y., Thompson W., and Biancani P. Inositol trisphosphate restores impaired human gallbladder motility associated with cholesterol stones. Gastroenterology 104 (1993) 563-568
5. Beinborn M., Quinn S.M., and Kopin A.S. Minor modifications of a cholecystokinin-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties. J Biol Chem 273 (1998) 14146-14151
6. Beinborn M., Ren Y., Blaker M., Chen C., and Kopin A.S. Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms. Mol Pharmacol 65 (2004) 753-760
7. Blakeney J.S., Reid R.C., Le G.T., and Fairlie D.P. Nonpeptidic ligands for peptide-activated G protein-coupled receptors. Chem Rev 107 (2007) 2960-3041
8. Bläker M., Ren Y., Seshadri L., McBride E.W., Beinborn M., and Kopin A.S. CCK-B/gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides. Mol Pharmacol 58 (2000) 399-406
9. Bouvier M., Moffett S., Loisel T.P., Mouillac B., Hebert T., and Chidiac P. Palmitoylation of G-protein-coupled receptors: a dynamic modification with functional consequences. Biochem Soc Trans 23 (1995) 116-120
10. Conn P.M., Knollman P.E., Brothers S.P., and Janovick J.A. Protein folding as posttranslational regulation: evolution of a mechanism for controlled plasma membrane expression of a G protein-coupled receptor. Mol Endocrinol 20 (2006) 3035-3041
11. Cremonini F., Camilleri M., McKinzie S., Carlson P., Camilleri C.E., Burton D., et al. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 100 (2005) 652-663
12. Dabrowski A., Detjen K.M., Logsdon C.D., and Williams J.A. Stimulation of both CCK-A and CCK-B receptors activates MAP kinases in AR42J and receptor-transfected CHO cells. Digestion 58 (1997) 361-367
13. Dawson E.S., Henne R.M., Miller L.J., and Lybrand T.P. Molecular models for cholecystokinin-A receptor. Pharmacol Toxicol 91 (2002) 290-296
14. Ding X.Q., Dolu V., Hadac E.M., Holicky E.L., Pinon D.I., Lybrand T.P., et al. Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminaI probe. J Biol Chem 276 (2001) 4236-4244
15. Ding X.Q., Dolu V., Hadac E.M., Schuetz M., and Miller L.J. Disulfide bond structure and accessibility of cysteines in the ectodomain of the cholecystokinin receptor: specific mono-reactive receptor constructs examine charge-sensitivity of loop regions. Recept Chan 9 (2003) 83-91
16. Ding X.Q., Pinon D.I., Furse K.E., Lybrand T.P., and Miller L.J. Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor. Mol Pharmacol 61 (2002) 1041-1052
17. Ding X.Q., Rao R.V., Kuntz S.M., Holicky E.L., and Miller L.J. Impaired resensitization and recycling of the cholecystokinin receptor by Co-expression of its second intracellular loop. Mol Pharmacol 58 (2000) 1424-1433
18. Dockray G.J. Clinical endocrinology and metabolism. Gastrin. Clin Endocrinol Metab 18 (2004) 555-568
19. Dockray G.J., Varro A., Dimaline R., and Wang T. The gastrins: their production and biological activities. Annu Rev Physiol 63 (2001) 119-139
20. Dong M., Ding X.Q., Thomas S.E., Gao F., Lam P.C., Abagyan R., et al. Role of lysine187 within the second extracellular loop of the type A cholecystokinin receptor in agonist-induced activation. Use of complementary charge-reversal mutagenesis to define a functionally important interdomain interaction. Biochemistry 46 (2007) 4522-4531
21. Dong M., Liu G., Pinon D.I., and Miller L.J. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling. Biochemistry 44 (2005) 6693-6700
22. Dufresne M., Seva C., and Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev 86 (2006) 805-847
23. Escrieut C., Gigoux V., Archer E., Verrier S., Maigret B., Behrendt R., et al. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor - Evidence for a crucial role of Met-121 in the activation process. J Biol Chem 277 (2002) 7546-7555
24. Eysselein V.E., Eberlein G.A., Hesse W.H., Schaeffer M., Grandt D., Williams R., et al. Molecular variants of cholecystokinin after endogenous stimulation in humans: a time study. Am J Physiol 258 (1990) G951-G957
25. Freidinger R.M. Cholecystokinin and gastrin antagonists. Med Res Rev 9 (1989) 271-290
26. Galés C., Kowalski-Chauvel A., Dufour M.N., Seva C., Moroder L., Pradayrol L., et al. Mutation of Asn-391 within the conserved NPXXY motif of the cholecystokinin B receptor abolishes Gq protein activation without affecting its association with the receptor. J Biol Chem 275 (2000) 17321-17327
27. Galés C., Poirot M., Taillefer J., Maigret B., Martinez J., Moroder L., et al. Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis, and structure/affinity studies. Mol Pharmacol 63 (2003) 973-982
28. Gates L.K., Ulrich C.D., and Miller L.J. Multiple kinases phosphorylate the pancreatic cholecystokinin receptor in an agonist-dependent manner. Am J Physiol 264 (1993) G840-G847
29. Gigoux V., Escrieut C., Silvente-Poirot S., Maigret B., Gouilleux L., Fehrentz J.A., et al. Met-195 of the cholecystokinin-A receptor interacts with the sulfated tyrosine of cholecystokinin and is crucial for receptor transition to high affinity state. J Biol Chem 273 (1998) 14380-14386
30. Gigoux V., Escrieut C., Fehrentz J.A., Poirot S., Maigret B., Moroder L., et al. Arginine 336 and asparagine 333 of the human cholecystokinin-A receptor binding site interact with the penultimate aspartic acid and the C-terminal amide of cholecystokinin. J Biol Chem 274 (1999) 20457-20464
31. Gigoux V., Maigret B., Escrieut C., Silvente-Poirot S., Bouisson M., Fehrentz J.A., et al. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin. Protein Sci 8 (1999) 2347-2354
32. Gimpl G., Anders J., Thiele C., and Fahrenholz F. Photoaffinity labeling of the human brain cholecystokinin receptor overexpressed in insect cells-Solubilization, deglycosylation and purification. Eur J Biochem 237 (1996) 768-777
33. Go W.Y., Holicky E.L., Hadac E.M., Rao R.V., and Miller L.J. Identification of a domain in the carboxy terminus of CCK receptor that affects its intracellular trafficking. Amn J Physiol 275 (1998) G56-G62
34. Gouldson P., Legoux P., Carillon C., Delpech B., Le Fur G., Ferrara P., et al. The antagonist SR 146131 and the antagonist SR 27897 occupy different sites on the human CCK(1) receptor. Eur J Pharmacol 400 (2000) 185-194
35. Hadac E.M., Dawson E.S., Darrow J.W., Sugg E.E., Lybrand T.P., and Miller L.J. Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor. J Med Chem 49 (2006) 850-863
36. Hadac E.M., Ghanekar D.V., Holicky E.L., Pinon D.I., Dougherty R.W., and Miller L.J. Relationship between native and recombinant cholecystokinin receptors-role of differential glycosylation. Pancreas 13 (1996) 130-139
37. Hadac E.M., Pinon D.I., Ji Z., Holicky E.L., Henne R.M., Lybrand T.P., et al. Direct identification of a second distinct site of contact between cholecystokinin and its receptor. J Biol Chem 273 (1998) 12988-12993
38. Hadac E.M., Ji Z.S., Pinon D.I., Henne R.M., Lybrand T.P., and Miller L.J. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: Dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely. J Med Chem 42 (1999) 2105-2111
39. Harikumar K.G., and Miller L.J. Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor. J Biol Chem 280 (2005) 18631-18635
40. Harikumar K.G., Pinon D.I., and Miller L.J. Fluorescent indicators distributed throughout the pharmacophore of cholecystokinin provide insights into distinct modes of binding and activation of type A and B cholecystokinin receptors. J Biol Chem 281 (2006) 27072-27080
41. Harikumar K.G., Pinon D.I., Wessels W.S., Dawson E.S., Lybrand T.P., Prendergast F.G., et al. Measurement of intermolecular distances for the natural agonist peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer. Mol Pharmacol 65 (2004) 28-35
42. Harikumar K.G., Pinon D.L., Wessels W.S., Prendergast F.G., and Miller L.J. Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor. J Biol Chem 277 (2002) 18552-18560
43. Harikumar K.G., Clain J., Pinon D.I., Dong M., and Miller L.J. Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy. J Biol Chem 280 (2005) 1044-1050
44. Harikumar K.G., Puri V., Singh R.D., Hanada K., Pagano R.E., and Miller L.J. Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor. J Biol Chem 280 (2005) 2176-2185
45. Harvey R.F., and Read A.E. Effect of cholecystokinin on colonic motility and symptoms in patients with irritable bowel syndrome. Lancet (1973)
46. Henin J., Maigret B., Tarek M., Escrieut C., Fourmy D., and Chipot C. Probing a model of a GPCR/ligand complex in an explicit membrane environment: the human cholecystokinin-1 receptor. Biophys J 90 (2006) 1232-1240
47. Herranz R. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev 23 (2003) 559-605
48. Ivy A.C., and Oldberg E. A hormone mechanism for gallbladder contraction and evacuation. Am J Physiol 86 (1928) 599-613
49. 100 in the second transmembrane domain of the cholecystokinin B receptor increases antagonist binding and reduces signal transduction. Mol Pharmacol 48 (1995) 783-789
50. Jagerschmidt A., Guillaume N., Roques B.P., and Noble F. Binding sites and transduction process of the cholecystokinin, receptor: involvement of highly conserved aromatic residues of the transmembrane domains evidenced by site-directed mutagenesis. Mol Pharmacol 53 (1998) 878-885
51. A receptor antagonist selectivity. Eur J Pharmacol 296 (1996) 97-106
52. Janovick J.A., Brothers S.P., Knollman P.E., and Conn P.M. Specializations of a G-protein-coupled receptor that appear to aid with detection of frequency-modulated signals from its ligand. FASEB J 21 (2007) 384-392
53. Ji Z., Hadac E.M., Henne R.M., Patel S.A., Lybrand T.P., and Miller L.J. Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling. J Biol Chem 272 (1997) 24393-24401
54. Kalindjian S.B., and McDonald I.M. Strategies for the design of non-peptide CCK2 receptor agonist and antagonist ligand. Cur Top Med Chem 7 (2007) 1195-1204
55. Kamath P.S., Gaisano H.Y., Phillips S.F., Miller L.J., Charboneau J.W., Brown M.L., et al. Abnormal gallbladder motility in irritable bowel syndrome: evidence for target-organ defect. Am J Physiol 260 (1991) G815-G819
56. Kellow J.E., Miller L.J., Phillips S.F., Zinsmeister A.R., and Charboneau J.W. Altered sensitivity of the gallbladder to cholecystokinin octapeptide in irritable bowel syndrome. Amn J Physiol 253 (1987) G650-G655
57. Kennedy K., Escrieut C., Dufresne M., Clerc P., Vaysse N., and Fourmy D. Identification of a region of the N-terminal of the human CCKA receptor essential for the high affinity interaction with agonist CCK. Biochem Biophys Res Commun 213 (1995) 845-852
58. Kennedy K., Gigoux V., Escrieut C., Martinez J., Moroder L., Frehel D., et al. Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin. J Biol Chem 272 (1997) 2920-2926
59. Klueppelberg U.G., Gates L.K., Gorelick F.S., and Miller L.J. Agonist-regulated phosphorylation of the pancreatic cholecystokinin receptor. J Biol Chem 266 (1991) 2403-2408
60. Kolakowski L.F. GCRDb: a G-protein-coupled receptor database. Recept Chans 2 (1994) 1-7
61. Kopin A.S., Beinborn M., Lee Y.M., McBride E.W., and Quinn S.M. The CCK-B/gastrin receptor. Identification of amino acids that determine nonpeptide antagonist affinity. Ann NY Acad Sci 713 (1994) 67-78
62. Kopin A.S., Lee Y.M., McBride E.W., Miller L.J., Lu M., Lin H.Y., et al. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A 89 (1992) 3605-3609
63. Kopin A.S., McBride E.W., Quinn S.M., Kolakowski Jr. L.F., and Beinborn M. The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands. J Biol Chem 270 (1995) 5019-5023
64. Langer I., Tikhonova I.G., Travers M.A., rcher-Lahlou E., Escrieut C., Maigret B., et al. Evidence that interspecies polymorphism in the human and rat cholecystokinin receptor-2 affects structure of the binding site for the endogenous agonist cholecystokinin. J Biol Chem 280 (2005) 22198-22204
65. Liddle R.A. Cholecystokinin. In: Walsh J.H., and Dockray G.J. (Eds). Gut peptides: biochemistry and physiology (1994), Raven Press, New York 175-216
66. Marco E., Foucaud M., Langer I., Escrieut C., Tikhonova I.G., and Fourmy D. Mechanism of activation of a G protein-coupled receptor, the human cholecystokinin-2 receptor. J Biol Chem 282 (2007) 28779-28790
67. Martin-Martinez M., Marty A., Jourdan M., Escrieut C., Archer E., Gonzalez-Muniz R., et al. Combination of molecular modeling, site-directed mutagenesis, and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor. J Med Chem 48 (2005) 4842-4850
68. Miller L.J. Heterogeneity of CCK receptors: classification and characterization. In: Adler G., and Beglinger C. (Eds). CCK antagonists in gastroenterology. Basic and clinical status. 1 ed. (1991), Springer-Verlag, Berlin 27-34
69. Miller L.J., Jardine I., Weissman E., Go V.L., and Speicher D. Characterization of cholecystokinin from the human brain. J Neurochem 43 (1984) 835-840
70. Miller L.J., and Lybrand T.P. Molecular basis of agonist binding to the type A cholecystokinin receptor. Pharmacol Toxicol 91 (2002) 282-285
71. Noble F. Pharmacology of CCKRs and SAR studies of peptidic analog ligands. Cur Top Med Chem 7 (2007) 1173-1179
72. Noble F., and Roques B.P. CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Prog Neurobiol 58 (1999) 349-379
73. Ozcelebi F., Holtmann M.H., Rentsch R.U., Rao R.V., and Miller L.J. Agonist-stimulated phosphorylation of the carboxyl-terminal tail of the secretin receptor. Mol Pharmacol 48 (1995) 818-824
74. Ozcelebi F., and Miller L.J. Phosphopeptide mapping of cholecystokinin receptors on agonist-stimulated native pancreatic acinar cells. J Biol Chem 270 (1995) 3435-3441
75. Ozcelebi F., Rao R.V., Holicky E., Madden B.J., McCormick D.J., and Miller L.J. Phosphorylation of cholecystokinin receptors expressed on Chinese hamster ovary cells: similarities and differences relative to native pancreatic acinar cells. J Biol Chem 271 (1996) 3750-3755
76. Paillasse M.R., Deraeve C., de M.P., Mhamdi L., Favre G., Poirot M., et al. Insights into the cholecystokinin 2 receptor binding site and processes of activation. Mol Pharmacol 70 (2006) 1935-1945
77. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 (2000) 739-745
78. Pearson R.K., and Miller L.J. Affinity labeling of a novel cholecystokinin-binding protein in rat pancreatic plasmalemma using new short probes for the receptor. J Biol Chem 262 (1987) 869-876
79. Pellegrini M., and Mierke D.F. Molecular complex of cholecystokinin-8 and N-terminus of the cholecystokinin A receptor by NMR spectroscopy. Biochemistry 38 (1999) 14775-14783
80. Pohl M., Silvente-Poirot S., Pisegna J.R., Tarasova N.I., and Wank S.A. Ligand-induced internalization of cholecystokinin receptors - Demonstration of the importance of the carboxyl terminus for ligand-induced internalization of the rat cholecystokinin type B receptor but not the type A receptor. J Biol Chem 272 (1997) 18179-18184
81. Rao R.V., Holicky E.L., Kuntz S.M., and Miller L.J. CCK receptor phosphorylation exposes regulatory domains affecting phosphorylation and receptor trafficking. Am J Physiol 279 (2000) C1986-C1992
82. Rao R.V., Roettger B.F., Hadac E.M., and Miller L.J. Roles of cholecystokinin receptor phosphorylation in agonist-stimulated desensitization of pancreatic acinar cells and receptor-bearing Chinese hamster ovary cholecystokinin receptor cells. Mol Pharmacol 51 (1997) 185-192
83. Rehfeld J.F. Cholecystokinin. Clin Gastroenterol 9 (1980) 593-607
84. Rehfeld J.F., Sun G., Christensen T., and Hillingso J.G. The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33. J Clin Endocrinol Metab 86 (2001) 251-258
85. Reubi J.C., Schaer J.C., and Waser B. Cholecystokinin (CCK)-A and CCK-B gastrin receptors in human tumors. Cancer Res 57 (1997) 1377-1386
86. Roettger B.F., Hellen E.H., Burghardt T.P., and Miller L.J. Multiple ligand and cell-dependent states of lateral mobility of plasmalemmal G protein-coupled cholecystokinin receptors. J Fluor 11 (2001) 237-246
87. Roettger B.F., Rentsch R.U., Hadac E.M., Hellen E.H., Burghardt T.P., and Miller L.J. Insulation of a G protein-coupled receptor on the plasmalemmal surface of the pancreatic acinar cell. J Cell Biol 130 (1995) 579-590
88. Roettger B.F., Rentsch R.U., Pinon D., Holicky E., Hadac E.M., Larkin J.M., et al. Dual pathways of internalization of the cholecystokinin receptor. J Cell Biol 128 (1995) 1029-1042
89. Silvente-Poirot S., Escrieut C., Galès C., Fehrentz J.A., Escherich A., Wank S.A., et al. Evidence for a direct interaction between the penultimate aspartic acid of cholecystokinin and histidine 207, located in the second extracellular loop of the cholecystokinin B receptor. J Biol Chem 274 (1999) 23191-23197
90. Silvente-Poirot S., Escrieut C., and Wank S.A. Role of the extracellular domains of the cholecystokinin receptor in agonist binding. Mol Pharmacol 54 (1998) 364-371
91. Silvente-Poirot S., and Wank S.A. A segment of five amino acids in the second extracellular loop of the cholecystokinin-B receptor is essential for selectivity of the peptide agonist gastrin. J Biol Chem 271 (1996) 14698-14706
92. Snape W.J., Carlson G.M., Matarazzo S.A., and Cohen S. Evidence that abnormal myoelectrical activity produces colonic motor dysfunction in the irritable bowel syndrome. Gastroenterology 72 (1977) 383-387
93. Steer M.L., and Meldolesi J. The cell biology of experimental pancreatitis. N Engl J Med 316 (1987) 144-150
94. B and neurotensin receptors. Br J Pharmacol 121 (1997) 310-316
95. Wang H.L. Basic amino acids at the C-terminus of the third intracellular loop are required for the activation of phospholipase C by cholecystokinin-B receptors. J Neurochem 68 (1997) 1728-1735
96. Wu S.V., Yang M., Avedian D., Birnbaumer M., and Walsh J.H. Single amino acid substitution of serine-82 to asparagine in first intracellular loop of human cholecystokinin (CCK)-B receptor confers full cyclic AMP responses to CCK and gastrin. Mol Pharmacol 55 (1999) 795-803
97. Wu V., Yang M., McRoberts J.A., Ren J., Seensalu R., Zeng N., et al. First intracellular loop of the human cholecystokinin-A receptor is essential for cyclic AMP signaling in transfected HEK-293 cells. J Biol Chem 272 (1997) 9037-9042
98. Xiao Z.L., Chen Q., Amaral J., Biancani P., and Behar J. Defect of receptor-G protein coupling in human gallbladder with cholesterol stones. Am J Physiol 278 (2000) G251-G258
99. Xiao Z.L., Chen Q., Amaral J., Biancani P., Jensen R.T., and Behar J. CCK receptor dysfunction in muscle membranes from human gallbladders with cholesterol stones. Am J Physiol 276 (1999) G1401-G1407
100. Yu P., Chen Q., Harnett K.M., Amaral J., Biancani P., and Behar J. Direct G protein activation reverses impaired CCK signaling in human gallbladders with cholesterol stones. Am J Physiol 269 (1995) G659-G665